Oxazaphosphorine toxicity reduction by mesna.
Hilgard
P
P
ASTA Pharma AG, Department of Cancer Research, Bielefeld, F.R.G.
Pohl
J
J
D001711:Biotransformation; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D015080:Mesna / Q000494:pharmacology / Q000627:therapeutic use*; D001745:Urinary Bladder Diseases / Q000139:chemically induced / Q000517:prevention & control
D003520:Cyclophosphamide; D015080:Mesna; D002945:Cisplatin